Angiotensin II Type 1 Receptor Blockers
"Angiotensin II Type 1 Receptor Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
| Descriptor ID |
D047228
|
| MeSH Number(s) |
D27.505.519.162.500
|
| Concept/Terms |
Angiotensin II Type 1 Receptor Blockers- Angiotensin II Type 1 Receptor Blockers
- Angiotensin II Type 1 Receptor Antagonists
- Type 1 Angiotensin Receptor Blockers
- Angiotensin 2 Type 1 Receptor Antagonists
- Type 1 Angiotensin Receptor Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II Type 1 Receptor Blockers".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II Type 1 Receptor Blockers".
This graph shows the total number of publications written about "Angiotensin II Type 1 Receptor Blockers" by people in this website by year, and whether "Angiotensin II Type 1 Receptor Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 5 | 1 | 6 |
| 2007 | 2 | 2 | 4 |
| 2008 | 4 | 3 | 7 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 3 | 5 |
| 2013 | 2 | 2 | 4 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin II Type 1 Receptor Blockers" by people in Profiles.
-
Losartan May Not Prevent Vestibular Schwannoma Growth or Related Hearing Loss During Observation. Otol Neurotol. 2024 Jul 01; 45(6):690-695.
-
STOX1 deficiency is associated with renin-mediated gestational hypertension and placental defects. JCI Insight. 2021 01 25; 6(2).
-
A pilot clinical trial with losartan in Myhre syndrome. Am J Med Genet A. 2021 03; 185(3):702-709.
-
Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare. Cardiovasc Drugs Ther. 2020 08; 34(4):579-584.
-
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. J Pediatr. 2020 07; 222:213-220.e5.
-
Biologically Regulated Marrow Stimulation by Blocking TGF-?1 With Losartan Oral Administration Results in Hyaline-like Cartilage Repair: A Rabbit Osteochondral Defect Model. Am J Sports Med. 2020 03; 48(4):974-984.
-
Exploring the Evidence Implicating the Renin-Angiotensin System (RAS) in the Physiopathology of Mood Disorders. Protein Pept Lett. 2020; 27(6):449-455.
-
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.
-
Losartan, an Angiotensin II Type 1 Receptor Antagonist, Alleviates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain by Inhibiting Inflammatory Cytokines in the Dorsal Root Ganglia. Mol Neurobiol. 2019 Nov; 56(11):7408-7419.
-
Superoxide via Sp3 mechanism increases renal renin activity, renal AT1 receptor function, and blood pressure in rats. Am J Physiol Renal Physiol. 2018 11 01; 315(5):F1478-F1483.